Lineage Cell Therapeutics (LCTX) Stock Price

Lineage Cell Therapeutics Price

NYSE AMEX·CLOSED
1.08USD+0.0010 (+0.09 %)
Market closed

Revenue has compounded at 14.2% per year over the past 19 years to 14.56 M USD. Lineage Cell Therapeutics's net margin stands at -436.5%, up from -991.2% several years earlier. Analysts set a median price target of 3.06 USD, implying 183.1% above the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 5% above its 52-week low.

Lineage Cell Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Lineage Cell Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Lineage Cell Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Lineage Cell Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Lineage Cell Therapeutics Stock Price History
DateLineage Cell Therapeutics Price
8/24/20261.08 USD
8/21/20261.08 USD
8/20/20261.08 USD
8/19/20261.11 USD
8/18/20261.06 USD
8/14/20261.07 USD
8/13/20261.06 USD
8/12/20261.10 USD
8/11/20261.12 USD
8/10/20261.13 USD
8/7/20261.10 USD
8/6/20261.13 USD
8/5/20261.14 USD
8/4/20261.13 USD
8/3/20261.11 USD
7/31/20261.08 USD
7/30/20261.11 USD
7/29/20261.04 USD
7/27/20261.02 USD
7/23/20261.07 USD
7/22/20261.11 USD
7/21/20261.14 USD
7/20/20261.10 USD
7/17/20261.16 USD
7/16/20261.17 USD
7/15/20261.22 USD
7/14/20261.22 USD
7/13/20261.24 USD
7/10/20261.28 USD
7/9/20261.29 USD
7/8/20261.33 USD
7/7/20261.32 USD
7/6/20261.36 USD
7/2/20261.35 USD
7/1/20261.30 USD
6/30/20261.31 USD
6/29/20261.35 USD
6/26/20261.28 USD
6/25/20261.22 USD
6/24/20261.26 USD
6/23/20261.25 USD
6/22/20261.24 USD
6/18/20261.23 USD
6/17/20261.25 USD
6/16/20261.25 USD
6/15/20261.28 USD
6/12/20261.28 USD
6/11/20261.27 USD
6/10/20261.24 USD
6/9/20261.22 USD
6/8/20261.21 USD
6/5/20261.19 USD
6/4/20261.21 USD
6/3/20261.20 USD
6/2/20261.21 USD
6/1/20261.26 USD
5/29/20261.33 USD
5/28/20261.33 USD
5/27/20261.30 USD
5/26/20261.29 USD
5/22/20261.30 USD
5/21/20261.32 USD
5/20/20261.29 USD
5/19/20261.20 USD
5/18/20261.24 USD
5/15/20261.25 USD
5/14/20261.31 USD
5/13/20261.28 USD
5/12/20261.33 USD
5/11/20261.31 USD
5/8/20261.37 USD
5/7/20261.37 USD
5/6/20261.43 USD
5/5/20261.46 USD
5/4/20261.42 USD
5/1/20261.53 USD
4/30/20261.51 USD
4/29/20261.46 USD
4/28/20261.56 USD
4/27/20261.55 USD
4/24/20261.55 USD
4/23/20261.63 USD
4/22/20261.63 USD
4/21/20261.64 USD
4/20/20261.65 USD
4/17/20261.71 USD
4/16/20261.64 USD
4/15/20261.63 USD
4/14/20261.59 USD
4/13/20261.51 USD
4/10/20261.48 USD
4/9/20261.49 USD
4/8/20261.54 USD
4/7/20261.52 USD
4/6/20261.54 USD
4/2/20261.57 USD
4/1/20261.59 USD
3/31/20261.58 USD
3/30/20261.47 USD
3/27/20261.49 USD
3/26/20261.53 USD
3/25/20261.55 USD
3/24/20261.48 USD
3/23/20261.47 USD
3/20/20261.45 USD
3/19/20261.55 USD
3/18/20261.50 USD
3/17/20261.58 USD
3/16/20261.60 USD
3/13/20261.61 USD
3/12/20261.58 USD
3/11/20261.68 USD
3/10/20261.81 USD
3/9/20261.77 USD
3/6/20261.85 USD
3/5/20261.84 USD
3/4/20261.95 USD
3/3/20261.89 USD
3/2/20261.95 USD
2/27/20261.92 USD
2/26/20261.96 USD
2/25/20261.90 USD
2/24/20261.82 USD
2/23/20261.77 USD
2/20/20261.81 USD
2/19/20261.78 USD
2/18/20261.72 USD
2/17/20261.68 USD
2/13/20261.66 USD
2/12/20261.70 USD
2/11/20261.80 USD
2/10/20261.84 USD
2/9/20261.67 USD
2/6/20261.70 USD
2/5/20261.68 USD
2/4/20261.74 USD
2/3/20261.76 USD
2/2/20261.54 USD
1/30/20261.48 USD
1/29/20261.57 USD
1/28/20261.58 USD
1/27/20261.63 USD
1/26/20261.59 USD
1/23/20261.61 USD
1/22/20261.65 USD
1/21/20261.66 USD
1/20/20261.65 USD
1/16/20261.70 USD
1/15/20261.65 USD
1/14/20261.70 USD
1/13/20261.67 USD
1/12/20261.76 USD
1/9/20261.71 USD
1/8/20261.76 USD
1/7/20261.83 USD
1/6/20261.70 USD
1/5/20261.69 USD
1/2/20261.64 USD
12/31/20251.67 USD
12/30/20251.60 USD
12/29/20251.63 USD
12/26/20251.65 USD
12/24/20251.68 USD
12/23/20251.66 USD
12/22/20251.73 USD
12/19/20251.68 USD
12/18/20251.75 USD
12/17/20251.77 USD
12/16/20251.80 USD
12/15/20251.72 USD
12/12/20251.66 USD
12/11/20251.71 USD
12/10/20251.74 USD
12/9/20251.74 USD
12/8/20251.69 USD
12/5/20251.72 USD
12/4/20251.74 USD
12/3/20251.68 USD
12/2/20251.61 USD
12/1/20251.66 USD
11/28/20251.76 USD
11/26/20251.71 USD
11/25/20251.74 USD
11/24/20251.75 USD
11/21/20251.74 USD
11/20/20251.67 USD
11/19/20251.71 USD
11/18/20251.77 USD
11/17/20251.74 USD
11/14/20251.88 USD
11/13/20251.80 USD
11/12/20251.93 USD
11/11/20251.82 USD
11/10/20251.81 USD
11/7/20251.76 USD
11/6/20251.73 USD
11/5/20251.82 USD
11/4/20251.80 USD
11/3/20251.96 USD
10/31/20251.92 USD
10/30/20251.84 USD
10/29/20251.71 USD
10/28/20251.73 USD
10/27/20251.75 USD
10/24/20251.70 USD
10/23/20251.63 USD
10/22/20251.61 USD
10/21/20251.65 USD
10/20/20251.64 USD
10/17/20251.65 USD
10/16/20251.70 USD
10/15/20251.81 USD
10/14/20251.79 USD
10/13/20251.77 USD
10/10/20251.66 USD
10/9/20251.75 USD
10/8/20251.73 USD
10/7/20251.73 USD
10/6/20251.71 USD
10/3/20251.69 USD
10/2/20251.72 USD
10/1/20251.69 USD
9/30/20251.69 USD
9/29/20251.79 USD
9/26/20251.71 USD
9/25/20251.55 USD
9/24/20251.60 USD
9/23/20251.59 USD
9/22/20251.62 USD
9/19/20251.53 USD
9/18/20251.55 USD
9/17/20251.39 USD
9/16/20251.38 USD
9/15/20251.35 USD
9/12/20251.34 USD
9/11/20251.29 USD
9/10/20251.21 USD
9/9/20251.27 USD
9/8/20251.24 USD
9/5/20251.22 USD
9/4/20251.20 USD
9/3/20251.23 USD
9/2/20251.22 USD
8/29/20251.17 USD
8/28/20251.21 USD
8/27/20251.22 USD
8/26/20251.25 USD
Access this data via the Eulerpool API
Get Free API Key

Lineage Cell Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
8.95 M USD
-24.73 M USD
-21.49 M USD
Jan 1, 2024
9.50 M USD
-21.48 M USD
-18.61 M USD
Jan 1, 2025
14.56 M USD
-21.78 M USD
-63.53 M USD
Jan 1, 2026 (e)
15.93 M USD
-15.93 M USD
-15.78 M USD
Jan 1, 2027 (e)
10.35 M USD
-10.35 M USD
-21.04 M USD
Jan 1, 2028 (e)
46.14 M USD
-46.14 M USD
3.22 M USD
Jan 1, 2029 (e)
123.76 M USD
-123.76 M USD
50.63 M USD
Jan 1, 2030 (e)
599.79 M USD
-599.79 M USD
329.83 M USD

Lineage Cell Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 3:54 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
5.003.004.003.001.004.0014.008.009.0014.0015.0010.0046.00123.00599.00281.00
-28.57-40.0033.33-25.00-66.67300.00250.00-42.8612.5055.567.14-33.33360.00167.39386.99-53.09
100.00100.00100.00100.00100.0050.0092.86100.00100.00100.00100.00100.00100.00100.00100.00100.00
5.003.004.003.001.002.0013.008.009.0014.0015.0010.0046.00123.00599.00281.00
-58.00-40.00-40.00-38.00-26.00-49.00-22.00-24.00-21.00-21.00-15.00-10.00-46.00-123.00-599.00–
-1,160.00-1,333.33-1,000.00-1,266.67-2,600.00-1,225.00-157.14-300.00-233.33-150.00-100.00-100.00-100.00-100.00-100.00–
33.00-19.00-45.00-11.00-20.00-43.00-26.00-21.00-18.00-63.00-15.00-21.003.0050.00329.00154.00
-170.21-157.58136.84-75.5681.82115.00-39.53-19.23-14.29250.00-76.1940.00-114.291,566.67558.00-53.19
99.55114.48126.90145.53150.04164.50169.79172.66200.19230.12230.12230.12230.12230.12230.12230.12
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Lineage Cell Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Lineage Cell Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Lineage Cell Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Lineage Cell Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Lineage Cell Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Lineage Cell Therapeutics stock margins

The Lineage Cell Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lineage Cell Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lineage Cell Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
67.28 %
-1,133.87 %
-991.24 %
Jan 1, 2022
95.10 %
-153.20 %
-178.71 %
Jan 1, 2023
92.50 %
-276.50 %
-240.20 %
Jan 1, 2024
96.48 %
-226.11 %
-195.90 %
Jan 1, 2025
99.00 %
-149.62 %
-436.47 %
Jan 1, 2026 (e)
99.00 %
-100.00 %
-99.07 %
Jan 1, 2027 (e)
99.00 %
-100.00 %
-203.28 %
Jan 1, 2028 (e)
99.00 %
-100.00 %
6.98 %

Lineage Cell Therapeutics Stock Revenue, EBIT, Earnings per Share

The Lineage Cell Therapeutics earnings per share therefore indicates how much revenue Lineage Cell Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.03 USD
-0.30 USD
-0.26 USD
Jan 1, 2022
0.09 USD
-0.13 USD
-0.15 USD
Jan 1, 2023
0.05 USD
-0.14 USD
-0.12 USD
Jan 1, 2024
0.05 USD
-0.11 USD
-0.09 USD
Jan 1, 2025
0.06 USD
-0.09 USD
-0.28 USD
Jan 1, 2026 (e)
0.07 USD
-0.07 USD
-0.07 USD
Jan 1, 2027 (e)
0.04 USD
-0.04 USD
-0.09 USD
Jan 1, 2028 (e)
0.20 USD
-0.20 USD
0.01 USD

Lineage Cell Therapeutics business model & stock analysis

Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide.

Lineage Cell Therapeutics SWOT Analysis

Strengths

Lineage Cell Therapeutics Inc possesses several key strengths that contribute to its competitive advantage:

  • Strong Research and Development Capabilities: Lineage Cell Therapeutics Inc boasts a robust research and development team that consistently generates innovative scientific breakthroughs.
  • Patented Technologies and Intellectual Property: The company owns a significant portfolio of patents and intellectual property rights, providing a strong foundation for future growth and product development.
  • Established Partnerships: Lineage Cell Therapeutics Inc has established strategic partnerships with leading pharmaceutical companies, facilitating access to additional resources and expertise.
  • Well-regarded Management Team: The company is led by a talented and experienced management team with a proven track record in the biotechnology industry.

Weaknesses

Despite its strengths, Lineage Cell Therapeutics Inc faces several weaknesses that could impede its progress:

  • Limited Financial Resources: The company has struggled to secure adequate funding to support its ambitious research and development efforts, potentially hindering future expansion.
  • Narrow Product Portfolio: Lineage Cell Therapeutics Inc currently relies heavily on a limited number of product candidates, making it vulnerable to market shifts and competitive pressures.
  • Regulatory Challenges: Developing and commercializing advanced cell-based therapies requires navigating complex regulatory pathways, increasing the risk of delays and compliance issues.
  • Reliance on Unproven Technologies: The success of Lineage Cell Therapeutics Inc largely depends on the viability and market acceptance of its innovative cell therapy technologies, which are still in early stages of development.

Opportunities

Several opportunities exist for Lineage Cell Therapeutics Inc to capitalize on:

  • Expanding Market Demand: The growing demand for novel cell-based therapies in the healthcare industry presents significant growth opportunities for Lineage Cell Therapeutics Inc.
  • Emerging Markets: The company can explore expansion into emerging markets, where there may be a greater need for affordable and accessible cell therapies.
  • Strategic Collaborations: Lineage Cell Therapeutics Inc can further strengthen its position through collaborations with academic institutions, research organizations, and industry partners.
  • Technological Advancements: Rapid advancements in biotechnology offer opportunities for Lineage Cell Therapeutics Inc to leverage new technologies and enhance its product offerings.

Threats

Lineage Cell Therapeutics Inc should be mindful of the following threats that could impact its operations:

  • Intense Competition: The biotechnology industry is highly competitive, and Lineage Cell Therapeutics Inc faces competition from both established players and emerging startups.
  • Regulatory and Legal Challenges: Compliance with evolving regulations, potential litigation, and intellectual property disputes pose significant threats to Lineage Cell Therapeutics Inc's operations and market access.
  • Market Volatility: The market for cell-based therapies can be volatile, influenced by factors such as public perception, regulatory changes, and economic conditions.
  • Uncertain Commercialization Success: The successful commercialization of Lineage Cell Therapeutics Inc's product candidates is uncertain, as it depends on the completion of clinical trials, regulatory approvals, and market acceptance.

Lineage Cell Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Lineage Cell Therapeutics Employees
Details
Date
Lineage Cell Therapeutics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Lineage Cell Therapeutics Segments

Lineage Cell Therapeutics Revenue by Segment (1/3)

  • 3 Years

  • Max

Collaboration Revenues
Royalties
Grant Revenues
Details
Date
Collaboration Revenues
Royalties
Grant Revenues
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
1.12 M USD
2.78 M USD
445,000.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD

Lineage Cell Therapeutics Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • Max

Collaboration Revenues
Grant Revenue
Royalties, License and Other Revenues
Royalties From Product Sales and License Fees
Grant
Subscription and Advertisement Revenues
Sale of Research Products and Services
Details
Date
Collaboration Revenues
Grant Revenue
Royalties, License and Other Revenues
Royalties From Product Sales and License Fees
Grant
Subscription and Advertisement Revenues
Sale of Research Products and Services
Jan 1, 2018
0.00 USD
3.57 M USD
0.00 USD
392,000.00 USD
0.00 USD
691,000.00 USD
333,000.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
773,000.00 USD
1.05 M USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
8.15 M USD
0.00 USD
1.35 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Lineage Cell Therapeutics Revenue by Segment (3/3)

  • 3 Years

  • 5 Years

  • Max

Grant Revenue
Royalties From Product Sales and License Fees
Sale of Research Products and Services
Details
Date
Grant Revenue
Royalties From Product Sales and License Fees
Sale of Research Products and Services
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
2.04 M USD
1.22 M USD
257,000.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD

Lineage Cell Therapeutics Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Revenue from area of domestic
United States
Asia
Foreign
Details
Date
Revenue from area of domestic
United States
Asia
Foreign
Jan 1, 2014
3.59 M USD
0.00 USD
1.66 M USD
0.00 USD
Jan 1, 2015
5.98 M USD
0.00 USD
1.06 M USD
0.00 USD
Jan 1, 2018
0.00 USD
1.80 M USD
0.00 USD
3.18 M USD
Jan 1, 2019
0.00 USD
2.09 M USD
0.00 USD
1.42 M USD
Jan 1, 2020
0.00 USD
1.16 M USD
0.00 USD
666,000.00 USD
Jan 1, 2021
0.00 USD
3.90 M USD
0.00 USD
446,000.00 USD

Lineage Cell Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Lineage Cell Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Lineage Cell Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Lineage Cell Therapeutics shares outstanding

The number of shares of Lineage Cell Therapeutics was 230.12 M in 2025. This indicates how many shares Lineage Cell Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
164.50 M Stocks
Jan 1, 2022
169.79 M Stocks
Jan 1, 2023
172.66 M Stocks
Jan 1, 2024
200.19 M Stocks
Jan 1, 2025
230.12 M Stocks
Jan 1, 2026 (e)
230.12 M Stocks
Jan 1, 2027 (e)
230.12 M Stocks
Jan 1, 2028 (e)
230.12 M Stocks

Lineage Cell Therapeutics stock splits

In Lineage Cell Therapeutics's history, there have been no stock splits.

Current Lineage Cell Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
84.62 % (11)
Hold
15.38 % (2)
Sell
0.00 % (0)
12M Price Target
3.06
Last Price
1.08
Currency
USD
12M Return Potential
183.07 %
LTM Return
0 %

Lineage Cell Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
7/14/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/4/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
3/25/2026
B. Riley Securities
B. Riley Securities
MaintainedBuy–
3/24/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/6/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
2/9/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
11/25/2025
D. Boral Capital
D. Boral Capital
MaintainedBuy–
11/24/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/27/2025
D. Boral Capital
D. Boral Capital
MaintainedBuy–
8/14/2025
D. Boral Capital
D. Boral Capital
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Lineage Cell Therapeutics Earnings Calls

2025

Lineage Cell Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.03USD-1.56 MUSD-2026 Q2
5/12/2026-0.02USD-3.67 MUSD-2026 Q1
3/5/2026-0.05USD-2.63 MUSD-2025 Q4
8/7/2025-0.03USD-1.50 MUSD-2025 Q2
11/14/2024-0.04USD-1.05 MUSD-2024 Q3
5/9/2024-0.04USD-709,236.00USD-2024 Q1
3/7/2024-0.04USD-1.16 MUSD-2023 Q4
11/8/2023-0.05USD-1.27 MUSD-2023 Q3
8/9/2023-0.03USD-4.78 MUSD-2023 Q2
5/10/2023-0.04USD-2.48 MUSD-2023 Q1

EESG©

Eulerpool ESG Scorecard© for the Lineage Cell Therapeutics stock

54/100
61
Environment
44
Social
58
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Lineage Cell Therapeutics shareholder structure

% Name
21.53740%
Broadwood Capital, Inc.
Broadwood Capital, Inc.
4.19105%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.96768%
Defender Capital LLC
Defender Capital LLC
2.33047%
Raffles Capital Management, LLC
Raffles Capital Management, LLC
1.99899%
Comerica, Inc.
Comerica, Inc.
1.66555%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
...

Lineage Cell Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
94.9%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
23.10%
NEAL C. BRADSHER
NEAL C. BRADSHER
SEC ↗
23.00%
BROADWOOD PARTNERS, L.P.
BROADWOOD PARTNERS, L.P.
SEC ↗
15.40%
George Karfunkel.
George Karfunkel.
SEC ↗
12.00%
GARY K. DUBERSTEIN
GARY K. DUBERSTEIN
SEC ↗
9.90%
(entities only): **
(entities only): **
SEC ↗
7.90%
13-3791931
13-3791931
SEC ↗
5.30%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
5.30%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
5.11%
04-2601915
04-2601915
SEC ↗
5.00%
Chernett Jorey
Chernett Jorey
SEC ↗

Lineage Cell Therapeutics Executives and Management Board

9 members · avg. age 59 · 44 % women

BC

Mr. Brian Culley (53)

Chief Executive Officer, Director · since 2018

2.53 M USD

Management

JH

Ms. Jill Howe (49)

Chief Financial Officer

1.11 M USD
GS

Mr. George Samuel (44)

General Counsel, Corporate Secretary

1.11 M USD

Board of Directors

MM

Mr. Michael Mulroy (59)

Independent Chairman of the Board

179,237.00 USD
DA

Ms. Deborah Andrews (67)

Independent Director

149,058.00 USD
NB

Mr. Neal Bradsher (59)

Independent Director

144,058.00 USD
AR

Mr. Angus Russell (69)

Independent Director

142,808.00 USD
DA

Dr. Dipti Amin (61)

Independent Director

129,058.00 USD
AJ

Dr. Anula Jayasuriya (68)

Independent Director

129,058.00 USD

Frequently asked questions about Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a biotechnology company focused on developing innovative cell therapies for various medical conditions. Their business model revolves around utilizing their proprietary cell-based technology platform to create therapeutic products that address unmet medical needs. By harnessing the potential of pluripotent stem cells, Lineage aims to develop and commercialize novel therapies that can restore or replace damaged or dysfunctional cells in the body. This approach has the potential to revolutionize the treatment of diseases such as Parkinson's, spinal cord injury, macular degeneration, and more. Through strategic collaborations and partnerships, Lineage Cell Therapeutics Inc aims to advance their pipeline of cell therapy candidates and bring transformative treatments to patients in need.

Lineage Cell Therapeutics Inc is primarily active in the biotechnology and regenerative medicine industries.

The main competitors of Lineage Cell Therapeutics Inc in the market are reputable companies such as Fate Therapeutics Inc, bluebird bio Inc, and Celularity Inc.

Lineage Cell Therapeutics Inc, formerly known as BioTime Inc, is a clinical-stage biotechnology company focused on developing novel cell therapies for various diseases. With a rich history dating back to 1992, the company has been at the forefront of regenerative medicine research. Lineage Cell Therapeutics is dedicated to using its proprietary cell-based technologies to treat degenerative disorders and diseases. The company's extensive research expertise and collaborations have contributed to groundbreaking advancements in stem cell therapy. By leveraging its broad portfolio of cell lines, including pluripotent and progenitor cells, Lineage Cell Therapeutics aims to revolutionize the field of regenerative medicine and improve patient outcomes.

Lineage Cell Therapeutics Inc, a leading biotechnology company, has achieved significant milestones in its journey. The company has made breakthrough advancements in the field of cell therapy, focusing on regenerative medicine and developing innovative treatments for degenerative diseases. Lineage Cell Therapeutics has successfully completed multiple clinical trials, demonstrating the safety and efficacy of its promising cell-based therapies. Additionally, the company has gained regulatory approvals and collaborated with renowned medical institutions to further its research and development efforts. With a dedicated team of experts and a commitment to improving patients' lives, Lineage Cell Therapeutics continues to make strides in the field of regenerative medicine.

Lineage Cell Therapeutics Inc is primarily present in the United States.

Lineage Cell Therapeutics Inc represents values of innovation, dedication, and excellence in the field of cell therapy. The company's corporate philosophy revolves around utilizing the potential of stem cells to address unmet medical needs and improve patients' lives. With a focus on research and development, Lineage Cell Therapeutics Inc aims to deliver groundbreaking therapies that can revolutionize the treatment of age-related macular degeneration and other degenerative diseases. By harnessing the power of regenerative medicine, the company strives to offer hope and a better quality of life for patients worldwide.

Analysts currently set an average price target of 4.25 USD for the Lineage Cell Therapeutics stock (median: 3.06 USD), implying +293.2 % versus the latest price. The consensus is based on 13 analyst ratings.

Lineage Cell Therapeutics Analyst Price Targets 2026

13 analysts currently rate the Lineage Cell Therapeutics stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Lineage Cell Therapeutics to generate revenue of 15.93 M USD and earnings per share of -0.07 USD.

Lineage Cell Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Lineage Cell Therapeutics share trades at 0.93 EUR (1.08 USD).

The Lineage Cell Therapeutics share (LCTX) is listed on 3 stock exchanges, including: Frankfurt (BT3.F).

Lineage Cell Therapeutics Inc is a US-based company specializing in the development of cell therapies for the treatment of various diseases. The company's business model is based on the production and marketing of cell therapies derived from human embryonic stem cells. The company has various divisions, including neurology, ophthalmology, immunology, and oncology. In neuroscience, the company focuses on the therapy of spinal cord injuries, strokes, Alzheimer's disease, and other neurodegenerative diseases. In ophthalmology, the company focuses on the treatment of retinal diseases such as age-related macular degeneration and diabetic retinopathy. In immunology, Lineage Cell Therapeutics focuses on the treatment of autoimmune diseases such as type 1 diabetes and multiple sclerosis. In oncology, the company focuses on the development of cancer immunotherapies. The flagship product of Lineage Cell Therapeutics is OpRegen, a cell therapy for the treatment of retinal diseases. OpRegen is a product derived from pluripotent stem cells. It is currently in clinical trials, and the company hopes to bring it to market in the near future. Another product of Lineage Cell Therapeutics is OPC1, a cell therapy for the treatment of spinal cord injuries. OPC1 utilizes human embryonic stem cells differentiated into oligodendrocytes to repair damaged nerve fibers in the spinal cord. The product is currently in phase 1/2 studies. Lineage Cell Therapeutics is also working on the development of cancer immunotherapies based on the use of genetically modified T cells that can recognize and attack cancer cells. These therapies aim to provide more effective and targeted treatment for cancer. The company's business model involves the development and marketing of cell therapies derived from human embryonic stem cells. Lineage Cell Therapeutics works closely with academic institutions and research partners to develop new treatments and expand therapy options for patients. To further expand its business model, the company has undertaken various strategic partnerships and acquisitions. In 2018, Lineage Cell Therapeutics acquired Asterias Biotherapeutics to strengthen its position in the treatment of spinal cord injuries. In the same year, the company also entered into a partnership with Cancer Research UK to develop new cancer immunotherapies. In summary, Lineage Cell Therapeutics Inc is a company specializing in the development and marketing of cell therapies for the treatment of various diseases. The company's business model is based on the use of human embryonic stem cells and a diverse product portfolio encompassing various divisions, including neuroscience, ophthalmology, immunology, and oncology. Through strategic partnerships and acquisitions, the company aims to strengthen its position in the industry and continue its mission to develop innovative treatment options for patients in need.

The expected revenue of Lineage Cell Therapeutics is 15.93 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Lineage Cell Therapeutics is -15.78 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lineage Cell Therapeutics is currently -15.76. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lineage Cell Therapeutics stock.

The price-to-sales ratio (P/S) of Lineage Cell Therapeutics is currently 15.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lineage Cell Therapeutics stock.

The Eulerpool Quality Score for Lineage Cell Therapeutics is 3/10.

The ISIN of Lineage Cell Therapeutics is US53566P1093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Lineage Cell Therapeutics is A2PP89. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Lineage Cell Therapeutics is LCTX. The ticker symbol is used to trade Lineage Cell Therapeutics shares on the stock exchange.

Lineage Cell Therapeutics paid dividends every year for the past 0 years.

Lineage Cell Therapeutics is assigned to the 'Health' sector.

The dividends of Lineage Cell Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Lineage Cell Therapeutics

Our stock analysis for Lineage Cell Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lineage Cell Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Revenue→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Net Income→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics P/E→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics P/S→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics EBIT→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Dividend→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Directors Dealings→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Stocks→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Market capitalization→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Debt→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Liabilities→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Equity→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics AAQS→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Employees→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics ROE→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics ROA→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics ROCE→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics News→
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Analyst Price Targets→

Health Stocks

Linical CoLincoln PharmaceuticalsLionco Pharmaceutical Group CoLin BioscienceLipella PharmaceuticalsLimitless X HoldingsLipocineLimes SchlossklinikenLiquidiaLiguaLisata TherapeuticsLigand PharmaceuticalsAll Stocks A–Z →